Cancers, Vol. 12, Pages 745: A Disintegrin and Metalloproteinase 9 (ADAM9) in Advanced Hepatocellular Carcinoma and Their Role as a Biomarker During Hepatocellular Carcinoma Immunotherapy
This study measured ADAM9 mRNA levels in blood samples of advanced HCC patients (n = 10). In newly diagnosed patients (n = 5), the plasma ADAM9 mRNA level was significantly higher than that in healthy controls (3.001 versus 1.00, p < 0.05). Among four patients treated with nivolumab therapy, two patients with clinical response to nivolumab showed significant decreases in fold changes of serum ADAM9 mRNA level from 573.98 to 262.58 and from 323.88 to 85.52 (p < 0.05); however, two patients with no response to nivolumab did not. Using the Cancer Genome Atlas database, we found that higher expression of ADAM9 in tumor tissues was associated with poorer survival of HCC patients (log-rank p = 0.00039), while ADAM10 and ADAM17 exhibited no such association. In addition, ADAM9 expression showed a positive correlation with the expression of inhibitory checkpoint molecules. This study, though small in sample size, clearly suggested that ADAM9 mRNA might serve as biomarker predicting clinical response and that the ADAM9-MICA-NKG2D system can be a good therapeutic target for HCC immunotherapy. Future studies are warranted to validate these findings.
Source: Cancers - Category: Cancer & Oncology Authors: Sooyeon Oh YoungJoon Park Hyun-Jung Lee Jooho Lee Soo-Hyeon Lee Young-Seok Baek Su-Kyung Chun Seung-Min Lee Mina Kim Young-Eun Chon Yeonjung Ha Yuri Cho Gi Jin Kim Seong-Gyu Hwang KyuBum Kwack Tags: Article Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Databases & Libraries | Hepatocellular Carcinoma | Immunotherapy | Liver Cancer | Study